Leiden-based biotech company ProQR bags 7.7MProQR Therapeutics secures $8.1 million to advance RNA therapies for Rett syndrome, focusing on MECP2 gene mutations.The Axiomer platform enables precise RNA edits, offering hope for treating genetic disorders.